Richard C. Zink
Senior Director, Data Management and Statistics, TARGET PharmaSolutions
Associate Editor Therapeutic Innovation & Regulatory Science
Q&A
When did you realize you wanted to work in statistics?
In undergrad, I quickly switched from a computer science degree to mathematics because I fell in love with the ability to solve problems with mathematics. At the time, I loved playing board games and strategy games, so most of my higher-level mathematics coursework was in probability theory. This naturally led me to courses in statistics where I greatly appreciated the ability to ask and answer questions of practical importance. My foremost thought was that I wanted to apply statistics to meaningful subject matter, so I applied for graduate training in biostatistics so that I could apply my skills to developing new medicines and improving patient well-being.
In your opinion, what is the greatest challenge in your field?
Any research that involves human beings is extraordinarily complex. There are ethical issues to consider, factors that are hard to measure and account for in the analysis, as well as patient reliability in showing up for visits or taking medications as required. Further, people lead complicated lives which can impact the findings in numerous ways.
What in your opinion is the biggest gap between research and practice in your field?
For statisticians, the biggest gap is often between the development of new methodologies and having those methodologies readily available for everyday use in statistical software.
Where do you see your field going? What is your vision of the field in 2030?
In the future, I hope to see statisticians and data scientists taking greater and greater leadership roles. Statistics and data science or so crucial to the success of most companies, I feel that every board or senior leadership team should include a statistician/data scientist. These individuals can communicate the importance of how data are derived, how they can be analyzed appropriately, and how results can be interpreted so that companies can make the most informed decisions possible.
What do you like most about your job?
I currently work at a real world data company. I love the ability to take my skills and experience from my past lives in the pharmaceutical and software industries to better understand patient disease burden and how other data sources can be used to answer questions of regulatory importance.
What is the first book you remember reading? And what book are you currently reading and why?
I am a big fan of dystopian literature. I remember being blown away by the book 1984 and how people could be controlled by convincing them to deny truths they had already experienced first-hand. I recently read Parable of the Sower by Octavia Butler. It is the first time in a very long time that I found a work of dystopian fiction so frightening, mostly because I could see how this particular vision of the future could come true. The big lesson from these books is the importance of balance in life. Things quickly fall apart if you become extreme and unyielding on any single point.
What advice would you give your younger self about to enter the “real world?”
I would tell myself to be open to new possibilities. There were many times in the past where I had stated most emphatically that I would not be interested in a particular life choice or career decision. In all cases, I ended up doing them all anyway. I would encourage the younger me to be more open-minded, because you never know what opportunities may become available.
How has DIA helped you?
DIA is important because it exposes me to the needs and expertise of the many disciplines required to improve the lives of patients. Statistics is one part of the puzzle, and insufficient on its own. However, the picture would be incomplete without the benefit of statistics. In the end, DIA stresses this collaboration.
BIOGRAPHY
Richard C. Zink is Senior Director of Data Management and Statistics at TARGET PharmaSolutions. He is the 2019 Chair of the Biopharmaceutical Section of the American Statistical Association, host of the Biopharmaceutical Section Statistics Podcast, and Associate Editor for the DIA journal Therapeutic Innovation & Regulatory Science. Richard is author, editor, and contributor to eight books on statistical topics in clinical trials and clinical research. He holds a PhD in Biostatistics from the University of North Carolina at Chapel Hill where he serves as Adjunct Assistant Professor of Biostatistics.
DIA Spotlights
-
Jonathan Andrus • Chief Business Officer, Clinical Ink
DIA Inspire Award Winner -
Catherine Baldridge • Principal Consultant & Owner, Essential Pharmacovigilance, LLC
DIA Community Leadership Council -
Kimberly Belsky • Executive Director, Regulatory Policy & Intelligence, Mallinckrodt Pharmaceuticals
DIA AdPromo Working Group Chair, DIA Regulatory Affairs Community -
Megan Bettle • Director, Centre for Regulatory Excellence, Statistics and Trials
Regional Editor Global Forum -
Stella Blackburn • Vice President, Global Head of Early Access and Risk Management, IQVIA
DIA Volunteer -
Poonam Bordoloi • Medical Affairs Team Lead, General Medicines, Global Scientific Content, Merck & Co., Inc.
DIA Volunteer -
Linda Bowen • Head of Regulatory Policy and Intelligence, Seattle Genetics; Assistant Professor, RAQA Program, Temple University
DIA Inspire Award Winner -
Joan Buenconsejo • Director and Biometrics Team Leader, Astra Zeneca
DIA Statistics Community Chair -
Gerald Dal Pan • Director, Office of Surveillance & Epidemiology, FDA’s Center for Drug Evaluation and Research
DIA Fellow -
Gaby Danan • former EU QPPV, Sanofi
DIA Fellow -
Richard Day • Professor of Clinical Pharmacology; University of New South Wales, Medicine, St. Vincent's Hospital
Fellow of DIA
Associate Editor TIRS
Regional Editor Global Forum -
Nancy Dreyer • Chief Scientific Officer and Senior Vice President, IQVIA
Fellow of DIA
DIA Inspire Award Winner -
E. Stewart Geary • Chief Medical Officer and a Senior Vice President, Eisai Co., Ltd.
DIA Fellow -
Alberto Grignolo • Corporate Vice President, Parexel
Fellow of DIA
Editor-in-Chief Global Forum -
Terry Katz • Head, Data Management and Statistics, Merck Animal Health
DIA GCP-QA Community Chair -
Agnes Klein • Senior Medical Advisor, Biologic and Radiopharmaceutical Drugs Directorate, Health Canada
DIA Volunteer -
Mark Kryah • Senior Advisor and COO, Pharmaceutical Project Management, Immunology, Eli Lilly and Company
DIA Project Management Community Chair -
Birka Lehmann • Senior Expert, Drug Regulatory Affairs; Lecturer, Friedrich Wilhelm University
Fellow of DIA -
Munish Mehra • Principal Biostatistician & Executive Director, Tigermed
DIA Inspire Award Winner
DIA Clinical Research Community Chair -
Lisa Mulcahy • Owner and Principal Consultant, Mulcahy Consulting, LLC
DIA Document and Records Management Community Chair -
Noriaki Murao • Short Term Consultant, World Health Organization, Western Pacific Region
DIA Fellow -
Robert Paarlberg • Principal, Paarlberg & Associates LLC
DIA Inspire Award Winner -
Kim Quaintance-Lunn • Vice President and Head, Regulatory Policy, North American Regulatory Affairs, Bayer
DIA Inspire Award Winner -
Matthew Reaney • Scientific Lead, Patient Centered Endpoints, IQVIA
DIA Study Endpoints Community Chair -
Jeffrey Sherman • Chief Medical Officer and Executive Vice President, Horizon Therapeutics
Fellow of DIA -
Meredith Smith • Director, Risk Management, Alexion Pharmaceuticals, Inc.; Adjunct Professor, School of Pharmacy, University of Southern California, Los Angeles
DIA Volunteer -
Ling Su • Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University; Venture Partner, Lilly Asia Ventures
Fellow of DIA -
Angela van der Salm • Director Pharmacovigilance, Managing Partner, DADA Consultancy
DIA Volunteer -
Casey Walker • PGY-1 Behavioral Health Pharmacy Resident, University of the Sciences of Philadelphia
DIA Inspire Award Winner -
Jingsong Wang • CEO, Harbour BioMed
DIA Inspire Award Winner -
Richard C. Zink • Senior Director, Data Management and Statistics, TARGET PharmaSolutions
Associate Editor Therapeutic Innovation & Regulatory Science